SCHEMBL1808550

SCHEMBL1808550

Cc1cc([N+](=O)[O-])c(C)cc1C=O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.49
CYP3A4 P08684 3/20 0.49
MAPT P10636 3/20 0.49
HSD17B10 Q99714 2/20 0.49
KDM4E B2RXH2 1/20 0.49
ALOX15 P16050 1/20 0.49
PRKDC P78527 1/20 0.49
TSHR P16473 4/20 0.44
CYP1A2 P05177 1/20 0.44
RECQL P46063 1/20 0.44
ERN1 O75460 3/20 0.43
SMN1; SMN2 Q16637 1/20 0.41
GRIA1 P42261 1/20 0.40
GRIA2 P42262 1/20 0.40
GRIA3 P42263 1/20 0.40
GRIA4 P48058 1/20 0.40
HSP90AA1 P07900 1/20 0.40
PKM P14618 1/20 0.40
HPGD P15428 1/20 0.40
HTT P42858 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29036632 0.92 CYP3A4 (0.49) ALDH1A1CYP3A4MAPTHSD17B10KDM4E
SCHEMBL9910897 0.88 CYP3A4 (0.58) ALDH1A1CYP3A4MAPTHSD17B10KDM4E
SCHEMBL7826900 0.86 ALDH1A1 (0.59) ALDH1A1CYP3A4MAPTHSD17B10KDM4E
SCHEMBL8528182 0.83 VCAM1 (0.46) ALDH1A1CYP3A4MAPTHSD17B10KDM4E
SCHEMBL22289051 0.83 VCAM1 (0.50) ALDH1A1CYP3A4MAPTHSD17B10KDM4E
SCHEMBL24253063 0.83 ERN1 (0.50) ALDH1A1CYP3A4MAPTHSD17B10KDM4E
SCHEMBL8053279 0.82 TSHR (0.58) ALDH1A1CYP3A4MAPTHSD17B10TSHR
SCHEMBL1771230 0.82 TSHR (0.43) ALDH1A1CYP3A4MAPTHSD17B10KDM4E
SCHEMBL6358033 0.79 ERN1 (0.47) ALDH1A1CYP3A4MAPTHSD17B10KDM4E
SCHEMBL531943 0.79 ALDH5A1 (0.50) ALDH1A1CYP3A4MAPTHSD17B10KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020157710-A1 4-SUBSTITUTED ISOXAZOLE/ISOXAZOLINE (HETERO) ARYLAMIDINE COMPOUNDS, PREPARATION AND USE THEREOF PI INDUSTRIES LTD. (IN) 2020-08-06 WO disclosed
WO-2017067837-A1 MICROBIOCIDAL PHENYLAMIDINE DERIVATIVES SYNGENTA PARTICIPATIONS AG (CH) 2017-04-27 WO disclosed
US-8445505-B2 Pyrimidine derivatives as kinase inhibitors IRM LLC (BM) 2013-05-21 US disclosed
EP-2331526-A2 PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS IRM LLC (BM) 2011-06-15 EP disclosed
US-20110112096-A1 PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS ITM LLC (BM) 2011-05-12 US disclosed
WO-2009158431-A2 COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS IRM LLC (BM) 2009-12-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110112096-A1 PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS IGF1R, TYMP, PDXK ALDH1A1 618/4885CYP3A4 3631/4885MAPT 4028/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.